No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
TRDA Entrada Therapeutics
- 14.050
- +0.170+1.22%
Close May 8 16:00 ET
- 14.050
- 0.0000.00%
Post 16:02 ET
474.31MMarket Cap20.36P/E (TTM)
14.245High13.490Low57.45KVolume13.520Open13.880Pre Close806.93KTurnover0.38%Turnover RatioLossP/E (Static)33.76MShares18.44052wk High1.76P/B213.94MFloat Cap10.62052wk Low--Dividend TTM15.23MShs Float36.850Historical High--Div YieldTTM5.44%Amplitude5.120Historical Low14.046Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Entrada Therapeutics: A Strong Buy on Robust Financials and Promising DMD Therapeutic Pipeline
Express News | Entrada Therapeutics Expects Cash Runway Through The Second Quarter Of 2026 With $327M In Cash, Cash Equivalents And Marketable Securities As Of March 31, 2024
Express News | Entrada Therapeutics Q1 2024 GAAP EPS $0.68 May Not Be Comparable To $(0.52) Estimate, Sales $59.120M May Not Be Comparable To $14.977M Estimate
Entrada Therapeutics | 10-Q: Quarterly report
Entrada Therapeutics 1Q EPS 68c >TRDA
Entrada Therapeutics 1Q EPS 68c >TRDA
Entrada Therapeutics Cash Runway Expected Through the 2Q of 2026 With $327M in Cash, Cash Equivalents and Marketable Securities as of March 31 >TRDA
Entrada Therapeutics Cash Runway Expected Through the 2Q of 2026 With $327M in Cash, Cash Equivalents and Marketable Securities as of March 31 >TRDA
Comments
Dipal Doshi lauds Dowden's talent in strategizing and operation in life sciences, contributing to the advancement of the ENTR-601-44 program, a diverse intracellular therapeutics pipeline, and the establishment of new Boston headquarters. Entrada expects Dowden's expanded role to have continuous positive impact.
Press Release: Entrada Therapeutics Promotes Nathan J. Dowden to President
Date: 6/22/2023
Hello everyone,
I just posted our gains recap with updated charts for the stocks I have created Deep Dives for.
Just so you know:
I don't make any money off any of the Deep Dives I post.
Could I? Maybe, but then I would be doing it for profit which is not something I looking for right now with my articles.
Recap:
Deep Dive Recap (LARGE GAINS). Date: 6/22/2023 | by Alkaline | Jun, 2023 | Medium
A two minute read with updated charts!
To be clear, my intentions are lo...
Hello everyone,
I just posted our gains recap with updated charts for the stocks I have created Deep Dives for.
Just so you know:
I don't make any money off any of the Deep Dives I post.
Could I? Maybe, but then I would be doing it for profit which is not something I looking for right now with my articles.
Recap:
Deep Dive Recap (LARGE GAINS). Date: 6/22/2023 | by Alkaline | Jun, 2023 | Medium
A two minute read with updated charts!
To be clear, my intentions are lo...
7
7
Related:
IPO-pedia | Chipmaker giant GlobalFoundries seeks $25 bln in IPO
$Informatica(INFA.US$ $GlobalFoundries(GFS.US$ $Fluence Energy(FLNC.US$ $Arteris(AIP.US$ $Rent the Runway(RENT.US$ $Candela Medical(CDLA.US$ $Ensemble Health Partners(ENSB.US$ $LianBio(LIAN.US$ $Solo Brands(DTC.US$ $Airsculpt Technologies(AIRS.US$ $Aura Biosciences(AURA.US$ $Entrada Therapeutics(TRDA.US$ $HireRight(HRT.US$ $Sonendo(SONX.US$ $Udemy(UDMY.US$
IPO-pedia | Chipmaker giant GlobalFoundries seeks $25 bln in IPO
$Informatica(INFA.US$ $GlobalFoundries(GFS.US$ $Fluence Energy(FLNC.US$ $Arteris(AIP.US$ $Rent the Runway(RENT.US$ $Candela Medical(CDLA.US$ $Ensemble Health Partners(ENSB.US$ $LianBio(LIAN.US$ $Solo Brands(DTC.US$ $Airsculpt Technologies(AIRS.US$ $Aura Biosciences(AURA.US$ $Entrada Therapeutics(TRDA.US$ $HireRight(HRT.US$ $Sonendo(SONX.US$ $Udemy(UDMY.US$
Expand 21
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg